News Categories
Resources For Living
Mesothelioma Forum
Legal Help Blog
Find a Doctor Near You
About Mesothelioma
Latest News
- Clinical Trial Spotlight: Pemetrexed (ALIMTA) Plu...
- Wake Forest School of Medicine and FirstHealth of ...
- Mesothelioma Patients Eligible for Air Transportat...
- Mesothelioma Awareness Day Proposed as National Ev...
- Tougher Toxic Chemical Legislation Being Considere...
- Texas Cancer Center Offers Hope to Mesothelioma Pa...
- Alimta Extends Life of Lung Cancer Patients
- Iron Range Mesothelioma Health Screenings Underway...
- Mesothelioma Specialists Offer Optimal Care
- Chaplains Offer Comfort to Patients
News Archives
- April 2007
- May 2007
- June 2007
- July 2007
- August 2007
- September 2007
- October 2007
- November 2007
- December 2007
- January 2008
- February 2008
- March 2008
- April 2008
- May 2008
- June 2008
- July 2008
- August 2008
- September 2008
- October 2008
- November 2008
- December 2008
- January 2009
- February 2009
- March 2009
- April 2009
- May 2009
- June 2009
- July 2009
- August 2009
- September 2009
- October 2009
- November 2009
- December 2009
- January 2010
- February 2010
- March 2010
Wednesday, October 21, 2009
Simcere Pharmaceutical Group, a Chinese pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals, has joined forces with OSI Pharmaceuticals, Inc. of the United States, to develop, manufacture, and market its KDR/Kit inhibitor OSI-930 in China. OSI, based in Long Island, NY, specialized in the discovery and development of innovative molecular targeted therapies. OSI-930 targets both cancer cell proliferation and blood vessel growth (angiogenesis) in selected tumors. In preclinical studies, OSI-930 shows broad efficacy in small cell lung cancer, non-small cell lung cancer, colorectal, gastric and other cancers. The drug is also being tested for the treatment of mesothelioma.
Dr. Colin Goddard, Chief Executive Officer of OSI Pharmaceuticals said, "As a leading Chinese pharmaceutical company with a successful track record of developing and commercializing oncology products in China, we are confident that Simcere has the right capabilities and resources to successfully manufacture, develop and market OSI-930 in China."
According to the World Health Organization, China will have the world's highest number of lung cancer patients, close to 1 million a year by 2025, if smoking and pollution are not effectively curbed.
Simcere stocks (NYSE: SCR) rose 10% yesterday after the news was announced.
Reference NCT00603356 on ClinicalTrials.gov for further information on OSI-930.
Labels: mesothelioma, Treatment News
posted by Nancy Meredith at 9:03 AM
